Phage‐derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biotechnology progress (Print)

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/btpr.1559PMID 22581629
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

  2023cited by this paper
• Bevacizumab in non-small-cell lung cancer: a review

  2011cited by this paper
• Identification of novel neutralizing single‐chain antibodies against vascular endothelial growth factor receptor 2

  2011cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

  2011cited by this paper
• Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

  2011cited by this paper
• Ramucirumab (IMC-1121B): a novel attack on angiogenesis.

  2010cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Preparation of extracellular domain 3 of human VEGF receptor‐2 and the monitoring of its real‐time binding to VEGF by biosensors

  2009cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.

  2008cited by this paper
• Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

  2007cited by this paper
• Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling

  2006cited by this paper
• Managing Patients Treated with Bevacizumab Combination Therapy

  2005cited by this paper
• The role of VEGF in the regulation of physiological and pathological angiogenesis.

  2005cited by this paper
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  2005cited by this paper
• ClusPro: a fully automated algorithm for protein-protein docking

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• The Protein Data Bank and structural genomics

  2003cited by this paper
• ZDOCK: An initial‐stage protein‐docking algorithm

  2003cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.

  2001cited by this paper
• Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*

  2000cited by this paper
• Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor*

  1998cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Isolation of high affinity human antibodies directly from large synthetic repertoires.

  1994cited by this paper
• CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

  1994cited by this paper
• By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

  1991cited by this paper

• Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions

  2023cites this paper
• Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

  2023cites this paper
• A comprehensive comparison between camelid nanobodies and single chain variable fragments

  2021cites this paper
• Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy

  2021cites this paper
• Isolation and characterization of a novel scFv antibody fragments specific for Hsp70 as a tumor biomarker

  2019cites this paper
• Periprostatic fat adipokine expression is correlated with prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localized disease

  2019cites this paper
• A VEGFR2–MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice

  2019cites this paper
• Purification of a Novel Anti-VEGFR2 Single Chain Antibody Fragment and Evaluation of Binding Affinity by Surface Plasmon Resonance

  2019cites this paper
• Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease

  2018cites this paper
• University of Dundee Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease Dahran,

  2018cites this paper
• Screening for novel peptides specifically binding to the surface of ectopic endometrium cells by phage display.

  2018cites this paper
• Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B

  2018cites this paper
• A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo

  2017cites this paper
• A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand

  2017cites this paper
• Advances in Monoclonal Antibodies Production and Cancer Therapy

  2016cites this paper
• Generation and characterization of a human nanobody against VEGFR-2

  2016cites this paper
• Aptamers as functional bionanomaterials for sensor applications

  2016cites this paper
• A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity

  2016cites this paper
• EVALUATION OF THE BINDING AND ANTI-ANGIOGENIC CAPACITY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 NANOBODY (ANTI-VEGFR2 NANOBODY)

  2015cites this paper
• Biomimetic sensor design.

  2015cites this paper
• Phage Display Selection of Antibody Fragments targeted to VEGFR-3 Dimerization Domain

  2014cites this paper
• Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2

  2014cites this paper
• Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells

  2013cites this paper
• Phage display—A powerful technique for immunotherapy

  2012cites this paper